FDA Investigator M Patriciaurphy Murphy

M Patriciaurphy Murphy has inspections in 16 countries as of 25 Oct 2023. M Patriciaurphy Murphy has collaborated with a combinined 3287 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
407
Last Inspection Date:
25 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
100003538
Country:
United States of America, Poland, Denmark, Canada, United Kingdom of Great Britain and Northern Ireland, Belgium, Serbia, Japan, Germany, Marshall Islands, Austria, India, Jamaica, Czechia, Netherlands
Co-Investigator(s):
Abby E Pelletier, Abraham M Maekele, Abthony C Warchut, Alan R Condon, Alfred P Pistorio, Alice C Silva, Allison E Sincek, Alysia M Salonia, Amanda E Lewin, PhD, Amy C Jordan, Andrew M Barlow, Andrew Saunders, Angela Mock, Angela Shepas, Anita R Michael, Anthony C Warchut, Anthony N Onianwa, Anthony W Thomas, Arindam Dasgupta, PhD, Barbara A Gullick, Betsy C Galliher, Byungja E Marciante, Camerson E Moore, Cara M Minelli, Carol G Rochester, Carr, Christine M Smith, Christopher B May, Christopher C Wilcox, Christopher Janik, Chunsheng Cai, PhD, Constance Desimone, Courtney N Long, Cynthia F Kleppinger, MD, Cynthia L Rakestraw, Darin S Wiegers, Daryl A Dewoskin, Dawn C Olenjack, Dawn M Braswell, Deborah A Greco, Diane C Thibodeau, Diane Kelley, Diane M Biron, Dien N Nguyen, Dominic R Frasca, Don A Leeseberg, Douglas Florentino, Dr. Sriram Subramaniam, PhD, Edmund F Mrak, Jr, Eduardo L Rodriguez, Edward J Janik, Ellen P Madigan, Emmanuel A Dimaano, Jr, Erich P Garger, Francis A Guidry, Frank J Koch, Gabriel E Muniz, Gabrielle J Swain, Gale E Ryan, Gary J Hagan, George T Allen, Jr, Gerald T O'connor, Hang N Guo, Hasan A Irier, PhD, Iram R Hassan, PhD, Ivis L Negron, Ivis Lnegron Torres, Jaclyn N Munsch, Jacqueline M Bowling, James M Kewley, James R Fleckenstein, James R Wormuth, Jamie S Mathews, Janete F Guardia, Jay M Patria, Jeanne F Broderick, Jeffrey A Sincek, Jeffrey J Thibodeau, Jocelyn T Ramos, John A Hollings, John D Mays, John J Thibodeau, John L Zaccone, Jonah S Ufferfilge, Jonathan G Matrisciano, Jorge E Martinez, Jose A Torres, Jose Acruz Gonzalez, Joseph J Vannelli, Joshua L Gibbs, Joyce A Kellett, Kara A Scheibner, PhD, Karen M Cooper, Karen Mcnabb Noon, Karen R Smallwood, Kent A Conforti, Khin Mang U, MD, Kimberly A Benson, Kristina J Donohue, Laurie B Frazier, LCDR Debra Emerson, LCDR Matthew J Morrison, Lequita M Mayhew, Linda L Green, Lori A Holmquist, Margaret A Foster, Margaret M Sands, Maricelys Mercado, Mark E Farrell, Mark R Mcclain, Martin J Guardia, Mary P Murphy, Matthew C Watson, Maya M Davis, Melkamu Getie Kebtie, PhD, Miah Jung, Michael C Ireland, Michael E Cimaglio, Michael G Mayfield, Michael J Kuchta, Michael J Leal, Michael P Anthony, Michael Serrano, Michelle Hawkins, Michelle M Noe, Michelle M Noe Varga, Michelle Rfrazier Jessen, PhD, Miguel A Martinez, Minerva Rogers, Mohsen Rajabi Abhari, FDA, Monica E Caphart, Mpris Inspector, Murray Kurzman, Nabil Nakhoul, Nasser Yazdani, Nealie C Newberger, Nichole B Murphy, Nina Yang, Normica G Facey, Osama A Khatib, Paraluman S Leonin, Paul A Licata, Paul E Stein, Paul L Yeh, Paul P Geraci, Paula M Laplant, Peter R Lenahan, Rachel T Evans, Rapti D Madurawe, Rebecca B Welch, Richard M Fejka, Richard W Berning, Robert E Davis, Robert G Antonsen, Jr, Robert M Barbosa, Robert Mo Brien, Rterry Bolen, Samuel L Murray, Sarah L Clark, Scotty L Hargrave, Sharon K Gershon, Sheri L Stephenson, Sherri N Rohlf, MD, Sherry M Nisson, Simone E Pitts, State Agency, Stephanie Mangigian, MS/OSH, RN, Stephen C Smith, Stephen R Souza, Sunita Pandey, Susan D Yuscius, Susanne M Richardson, MSc RAC ELS, Suzie L Kent, Tania E Vizcaino, Terri L Jones, Thomas D Clarida, Thomas W Garvin, Todd D Alspach, Toni S Sturgis, Traci C Kelm, Tyanna N Hadley, Victoria M Daddeo, William K Dagley

M Patriciaurphy Murphy's Documents

Publish Date Document Type Title
March, 2006 FDA 483 Elizabeth L. Hohmann, M.D. - Form 483, 2006-03-10
April, 2008 EIR Charles J. Cote, MD - EIR, 2008-04-30
March, 2012 FDA 483 Prof. Thomas Zeller, M.D. - Form 483, 2012-03-09
February, 2000 FDA 483 Praxair Inc. - Form 483, 2000-02-15
June, 2012 EIR Pfizer Laboratories Div Pfizer Inc - EIR, 2012-05-07
April, 2011 FDA 483 Dr. Andre Vertruyen - Form 483, 2011-04-07
January, 2007 FDA 483 Alexion Pharmaceuticals, Inc. - Form 483, 2007-01-19
February, 2005 EIR Alison Jones - EIR, 2005-02-18
October, 2010 FDA 483 Pfizer Inc. Groton Laboratories - Form 483, 2010-10-27
February, 2005 FDA 483 Alison Jones - Form 483, 2005-02-18
April, 2008 FDA 483 Charles J. Cote, MD - Form 483, 2008-04-30
January, 2001 FDA 483 Boehringer Ingelheim Pharmaceuticals, Inc. - Form 483, 2001-01-16
March, 2005 FDA 483 Stephen Rossner - Form 483, 2005-03-10
September, 2010 EIR Boehringer Ingelheim Pharmaceuticals, Inc. - EIR, 2010-09-01
June, 2012 EIR Pfizer Laboratories Div Pfizer Inc - EIR, 2012-06-06
October, 2013 EIR Moussa C. Mansour, MD - EIR, 2013-10-15
February, 2000 EIR World Health Products LLC - EIR, 2000-02-03
April, 2008 FDA 483 Response Charles J. Cote, MD - Form 483R, 2008-04-30
November, 2000 FDA 483 Michael Spiegel, MD - Form 483, 2000-11-14
April, 2015 EIR Gordana Joksic, PhD - EIR, 2015-04-23
March, 2000 EIR Sandor Timar, M.D. - EIR, 2000-03-03
January, 2000 EIR Pequote Pharmaceutical Network - EIR, 2000-01-06
March, 2005 EIR Stephen Rossner - EIR, 2005-03-10
March, 2000 FDA 483 Response Sandor Timar, M.D. - Form 483R, 2000-04-19
August, 2000 FDA 483 Cross Cancer Institute - Form 483, 2000-08-04
August, 2014 EIR Yale New Haven Hospital Radioactive Drug Research Committee - EIR, 2014-08-14
April, 2015 EIR Ruza Antic, MD - EIR, 2015-04-26
March, 2006 EIR Elizabeth L. Hohmann, M.D. - EIR, 2006-03-10
August, 2000 FDA 483 Response Nabholtz, Dr. J.M. - Form 483R, 2001-01-04
January, 2001 EIR Boehringer Ingelheim Pharmaceuticals, Inc. - EIR, 2001-01-16
April, 2012 EIR Pfizer Laboratories Div Pfizer Inc - EIR, 2012-04-30
March, 2015 EIR Stoltz, Randall R. Dr. - EIR, 2015-03-19
March, 2006 FDA 483 Response Elizabeth L. Hohmann, M.D. - Form 483R, 2006-03-16
April, 2000 FDA 483 Peter W. Heald, M.D. - Form 483, 2000-04-28
April, 2000 EIR Oread Inc. - EIR, 2000-04-03
January, 2012 FDA 483 William McGee - Form 483, 2012-01-13
January, 2000 EIR Michael Spiegel, MD - EIR, 2000-01-14
July, 2000 FDA 483 Harrison D. O. Aldrich - Form 483, 2000-07-28
February, 2012 FDA 483 University of Connecticut Health Center/IRB - Form 483, 2012-02-03
August, 2000 EIR Nabholtz, Dr. J.M. - EIR, 2000-08-04
August, 2014 FDA 483 Yale New Haven Hospital Radioactive Drug Research Committee - Form 483, 2014-08-14
September, 2010 FDA 483 Response Boehringer Ingelheim Pharmaceuticals, Inc. - Form 483R, 2010-09-14
April, 2000 EIR Peter W. Heald, M.D. - EIR, 2000-04-28
October, 2013 FDA 483 Response Moussa C. Mansour, MD - Form 483R, 2013-11-04

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more